T2 Biosystems, Inc. (LON:0A57)

Market Cap	44.11K -99.5%
Revenue (ttm)	5.73M -30.2%
Net Income	-32.05M
EPS	-3.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	375
Average Volume	12,175
Open	0.1500
Previous Close	0.1355
Day's Range	0.1500 - 0.1500
52-Week Range	0.1355 - 6.5320
Beta	n/a
RSI	22.88
Earnings Date	Feb 13, 2026

About T2 Biosystems

T2 Biosystems, Inc. engages in the development and commercialization of medical diagnostic products for critical unmet needs in the healthcare. Its products include T2Dx instrument, T2Candida panel, and T2Bacteria panel. The company was incorporated in 2006 and is based in Lexington, Massachusetts.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 113
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A57

Financial Performance

In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.

Financial numbers in USD